Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
AGL vs CVS vs UNH vs HUM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
AGL vs CVS vs UNH vs HUM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $1.01B | $111.40B | $335.60B | $29.67B |
| Revenue (TTM) | $5.82B | $407.90B | $449.71B | $137.20B |
| Net Income (TTM) | $-373M | $2.93B | $12.04B | $1.13B |
| Gross Margin | -3.9% | 13.9% | 18.8% | 14.0% |
| Operating Margin | -6.8% | 1.5% | 4.2% | 1.0% |
| Forward P/E | — | 12.2x | 20.2x | 27.7x |
| Total Debt | $37M | $93.59B | $78.39B | $12.94B |
| Cash & Equiv. | $174M | $8.51B | $24.36B | $4.20B |
AGL vs CVS vs UNH vs HUM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Agilon Health, Inc. (AGL) | 100 | 7.7 | -92.3% |
| CVS Health Corporat… (CVS) | 100 | 114.3 | +14.3% |
| UnitedHealth Group … (UNH) | 100 | 92.7 | -7.3% |
| Humana Inc. (HUM) | 100 | 55.5 | -44.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AGL vs CVS vs UNH vs HUM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AGL plays a supporting role in this comparison — it may shine differently against other peers.
CVS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 27.7x)
UNH is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
- 220.6% 10Y total return vs CVS's 3.5%
- 11.8% revenue growth vs AGL's -2.1%
- 2.7% margin vs AGL's -6.4%
HUM lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.8% revenue growth vs AGL's -2.1% | |
| Value | Lower P/E (12.2x vs 27.7x) | |
| Quality / Margins | 2.7% margin vs AGL's -6.4% | |
| Stability / Safety | Beta 0.05 vs AGL's 2.98 | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +34.7% vs AGL's -28.4% | |
| Efficiency (ROA) | 3.9% ROA vs AGL's -24.5%, ROIC 9.2% vs -203.2% |
AGL vs CVS vs UNH vs HUM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AGL vs CVS vs UNH vs HUM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CVS leads in 3 of 6 categories
UNH leads 2 • AGL leads 0 • HUM leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 77.3x AGL's $5.8B. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to AGL's -6.4%. On growth, HUM holds the edge at +23.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $5.8B | $407.9B | $449.7B | $137.2B |
| EBITDAEarnings before interest/tax | -$366M | $10.5B | $23.2B | $2.2B |
| Net IncomeAfter-tax profit | -$373M | $2.9B | $12.0B | $1.1B |
| Free Cash FlowCash after capex | -$77M | $7.4B | $19.7B | $1.3B |
| Gross MarginGross profit ÷ Revenue | -3.9% | +13.9% | +18.8% | +14.0% |
| Operating MarginEBIT ÷ Revenue | -6.8% | +1.5% | +4.2% | +1.0% |
| Net MarginNet income ÷ Revenue | -6.4% | +0.7% | +2.7% | +0.8% |
| FCF MarginFCF ÷ Revenue | -1.3% | +1.8% | +4.4% | +0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.3% | +6.2% | +2.0% | +23.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +140.0% | +63.1% | +0.7% | -4.6% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 25.1x trailing earnings, HUM trades at a 60% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than HUM's 16.9x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.0B | $111.4B | $335.6B | $29.7B |
| Enterprise ValueMkt cap + debt − cash | $873M | $196.5B | $389.6B | $38.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.48x | 62.81x | 27.95x | 25.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 12.19x | 20.19x | 27.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.11x | 16.70x | 16.87x |
| Price / SalesMarket cap ÷ Revenue | 0.17x | 0.28x | 0.75x | 0.23x |
| Price / BookPrice ÷ Book value/share | 7.92x | 1.47x | 3.31x | 1.68x |
| Price / FCFMarket cap ÷ FCF | — | 14.27x | 20.88x | 79.13x |
Profitability & Efficiency
UNH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-146 for AGL. AGL carries lower financial leverage with a 0.29x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs AGL's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -146.0% | +3.9% | +11.5% | +6.2% |
| ROA (TTM)Return on assets | -24.5% | +1.1% | +3.9% | +2.2% |
| ROICReturn on invested capital | -2.0% | +5.0% | +9.2% | +4.1% |
| ROCEReturn on capital employed | -108.4% | +6.1% | +9.7% | +4.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.29x | 1.24x | 0.77x | 0.73x |
| Net DebtTotal debt minus cash | -$137M | $85.1B | $54.0B | $8.7B |
| Cash & Equiv.Liquid assets | $174M | $8.5B | $24.4B | $4.2B |
| Total DebtShort + long-term debt | $37M | $93.6B | $78.4B | $12.9B |
| Interest CoverageEBIT ÷ Interest expense | -119.84x | 2.11x | 4.71x | 3.08x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $724 for AGL. Over the past 12 months, CVS leads with a +34.7% total return vs AGL's -28.4%. The 3-year compound annual growth rate (CAGR) favors CVS at 11.0% vs AGL's -54.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +260.1% | +10.6% | +10.6% | -6.2% |
| 1-Year ReturnPast 12 months | -28.4% | +34.7% | -3.2% | -1.0% |
| 3-Year ReturnCumulative with dividends | -90.6% | +36.6% | -19.9% | -51.9% |
| 5-Year ReturnCumulative with dividends | -92.8% | +17.0% | -2.6% | -43.3% |
| 10-Year ReturnCumulative with dividends | -92.2% | +3.5% | +220.6% | +59.8% |
| CAGR (3Y)Annualised 3-year return | -54.6% | +11.0% | -7.1% | -21.7% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than AGL's 2.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs AGL's 50.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.98x | 0.05x | 0.59x | 0.56x |
| 52-Week HighHighest price in past year | $119.50 | $88.63 | $395.52 | $315.35 |
| 52-Week LowLowest price in past year | $0.97 | $58.35 | $234.60 | $163.11 |
| % of 52W HighCurrent price vs 52-week peak | +50.8% | +98.5% | +93.5% | +78.4% |
| RSI (14)Momentum oscillator 0–100 | 60.4 | 69.3 | 75.9 | 76.6 |
| Avg Volume (50D)Average daily shares traded | 373K | 7.4M | 7.9M | 1.6M |
Analyst Outlook
Evenly matched — CVS and UNH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AGL as "Hold", CVS as "Buy", UNH as "Buy", HUM as "Hold". Consensus price targets imply 9.0% upside for CVS (target: $95) vs -59.6% for AGL (target: $25). For income investors, CVS offers the higher dividend yield at 3.06% vs HUM's 1.44%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $24.50 | $95.20 | $385.43 | $246.00 |
| # AnalystsCovering analysts | 25 | 41 | 52 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% | +2.4% | +1.4% |
| Dividend StreakConsecutive years of raises | — | 0 | 25 | 0 |
| Dividend / ShareAnnual DPS | — | $2.67 | $8.70 | $3.56 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% | +1.7% | +0.5% |
CVS leads in 3 of 6 categories (Valuation Metrics, Total Returns). UNH leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.
AGL vs CVS vs UNH vs HUM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AGL or CVS or UNH or HUM a better buy right now?
For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.
8% revenue growth year-over-year, versus -2. 1% for Agilon Health, Inc. (AGL). Humana Inc. (HUM) offers the better valuation at 25. 1x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate CVS Health Corporation (CVS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AGL or CVS or UNH or HUM?
On trailing P/E, Humana Inc.
(HUM) is the cheapest at 25. 1x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AGL or CVS or UNH or HUM?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -92. 8% for Agilon Health, Inc. (AGL). Over 10 years, the gap is even starker: UNH returned +220. 6% versus AGL's -92. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AGL or CVS or UNH or HUM?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Agilon Health, Inc. 's 2. 98β — meaning AGL is approximately 5790% more volatile than CVS relative to the S&P 500. On balance sheet safety, Agilon Health, Inc. (AGL) carries a lower debt/equity ratio of 29% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — AGL or CVS or UNH or HUM?
By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.
8% versus -2. 1% for Agilon Health, Inc. (AGL). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, AGL leads at 35. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AGL or CVS or UNH or HUM?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -6. 8% for Agilon Health, Inc. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -7. 1% for AGL. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AGL or CVS or UNH or HUM more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 27. 7x for Humana Inc. — 15. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CVS: 9. 0% to $95. 20.
08Which pays a better dividend — AGL or CVS or UNH or HUM?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), HUM (1. 4% yield) pay a dividend. AGL does not pay a meaningful dividend and should not be held primarily for income.
09Is AGL or CVS or UNH or HUM better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Agilon Health, Inc. (AGL) carries a higher beta of 2. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, AGL: -92. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AGL and CVS and UNH and HUM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AGL is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock; UNH is a large-cap quality compounder stock; HUM is a mid-cap quality compounder stock. CVS, UNH, HUM pay a dividend while AGL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.